High incidence of chronic graft-versus-host disease after myeloablative allogeneic stem cell transplantation for chronic lymphocytic leukemia in Sweden : graft-versus-leukemia effect protects against relapse
(2013) In Medical Oncology 30(4). p.762-762- Abstract
Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a potentially curative treatment option for eligible patients with chronic lymphocytic leukemia (CLL). However, it is known that cure of CLL is only possible if a graft-versus-leukemia effect is present. Between 1994 and 2007, 48 adults underwent allo-SCT for poor-risk CLL in Sweden. Of these, ten (21%) patients aged 24-53 years (median: 46 years) received myeloablative conditioning (MAC), based on TBI and cyclophosphamide. All MAC patients had refractory, poorly controlled CLL before allo-SCT (partial remission in 9/10 patients and progressive disease in one). The cumulative incidence of acute graft-versus-host disease (GVHD) grades II-IV was 30%. Nine patients developed... (More)
Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a potentially curative treatment option for eligible patients with chronic lymphocytic leukemia (CLL). However, it is known that cure of CLL is only possible if a graft-versus-leukemia effect is present. Between 1994 and 2007, 48 adults underwent allo-SCT for poor-risk CLL in Sweden. Of these, ten (21%) patients aged 24-53 years (median: 46 years) received myeloablative conditioning (MAC), based on TBI and cyclophosphamide. All MAC patients had refractory, poorly controlled CLL before allo-SCT (partial remission in 9/10 patients and progressive disease in one). The cumulative incidence of acute graft-versus-host disease (GVHD) grades II-IV was 30%. Nine patients developed chronic GVHD; extensive in four. Rates of nonrelapse mortality at 1, 3 and 10 years were 0, 10 and 20%, respectively. Two patients relapsed 36 and 53 months after transplantation. Six patients were still alive after a median follow-up time of 11.5 years (range 5.9-13.7). The probabilities of relapse-free and overall survival from 1, 3 and 5 years after transplantation were 100, 90 and 70%, and 100, 90 and 80%, respectively. Nevertheless, our analysis of long-term outcome after MAC allo-SCT for CLL suggests that younger patients with poorly controlled CLL may benefit from MAC allo-SCT.
(Less)
- author
- organization
- publishing date
- 2013-12
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Adult, Disease Progression, Female, Graft vs Host Disease, Graft vs Leukemia Effect, Hematopoietic Stem Cell Transplantation, Humans, Kaplan-Meier Estimate, Leukemia, Lymphocytic, Chronic, B-Cell, Male, Middle Aged, Sweden, Transplantation, Homologous, Young Adult
- in
- Medical Oncology
- volume
- 30
- issue
- 4
- pages
- 762 - 762
- publisher
- Humana Press
- external identifiers
-
- scopus:84886973685
- pmid:24214180
- ISSN
- 1559-131X
- DOI
- 10.1007/s12032-013-0762-x
- language
- English
- LU publication?
- yes
- id
- 8310bbf6-19f5-4982-bc93-3f8ed8ecf7b6
- date added to LUP
- 2016-05-24 17:15:30
- date last changed
- 2024-08-18 03:05:41
@article{8310bbf6-19f5-4982-bc93-3f8ed8ecf7b6, abstract = {{<p>Allogeneic hematopoietic stem cell transplantation (allo-SCT) is a potentially curative treatment option for eligible patients with chronic lymphocytic leukemia (CLL). However, it is known that cure of CLL is only possible if a graft-versus-leukemia effect is present. Between 1994 and 2007, 48 adults underwent allo-SCT for poor-risk CLL in Sweden. Of these, ten (21%) patients aged 24-53 years (median: 46 years) received myeloablative conditioning (MAC), based on TBI and cyclophosphamide. All MAC patients had refractory, poorly controlled CLL before allo-SCT (partial remission in 9/10 patients and progressive disease in one). The cumulative incidence of acute graft-versus-host disease (GVHD) grades II-IV was 30%. Nine patients developed chronic GVHD; extensive in four. Rates of nonrelapse mortality at 1, 3 and 10 years were 0, 10 and 20%, respectively. Two patients relapsed 36 and 53 months after transplantation. Six patients were still alive after a median follow-up time of 11.5 years (range 5.9-13.7). The probabilities of relapse-free and overall survival from 1, 3 and 5 years after transplantation were 100, 90 and 70%, and 100, 90 and 80%, respectively. Nevertheless, our analysis of long-term outcome after MAC allo-SCT for CLL suggests that younger patients with poorly controlled CLL may benefit from MAC allo-SCT.</p>}}, author = {{Machaczka, Maciej and Johansson, Jan-Erik and Remberger, Mats and Hallböök, Helene and Lazarevic, Vladimir Lj and Wahlin, Björn Engelbrekt and Omar, Hamdy and Wahlin, Anders and Juliusson, Gunnar and Kimby, Eva and Hägglund, Hans}}, issn = {{1559-131X}}, keywords = {{Adult; Disease Progression; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Sweden; Transplantation, Homologous; Young Adult}}, language = {{eng}}, number = {{4}}, pages = {{762--762}}, publisher = {{Humana Press}}, series = {{Medical Oncology}}, title = {{High incidence of chronic graft-versus-host disease after myeloablative allogeneic stem cell transplantation for chronic lymphocytic leukemia in Sweden : graft-versus-leukemia effect protects against relapse}}, url = {{http://dx.doi.org/10.1007/s12032-013-0762-x}}, doi = {{10.1007/s12032-013-0762-x}}, volume = {{30}}, year = {{2013}}, }